Exercise combined with lysine-inositol vitamin B12 promotes height growth in children with idiopathic short stature

Growth Horm IGF Res. 2023 Apr-Jun:69-70:101535. doi: 10.1016/j.ghir.2023.101535. Epub 2023 May 16.

Abstract

Objective: This study was aimed to systematically determine the effect of exercise combined with lysine-inositol vitamin B12 (VB12) therapy on the height of children with idiopathic short stature (ISS).

Methods: Sixty children with ISS were randomly divided into observation and control groups (N = 30). Each group was given lysine-inositol VB12 oral solution (10 mL bid). Simultaneously, the observation group exercised following the "ISS exercise instruction sheet". The height (H), growth velocity (GV), height standard deviation score (HtSDS) and other indicators were compared after 6 and 12 months of intervention, respectively. After 12 months of intervention, the biochemical indicators of the two groups, together with the correlation between the average days of exercise per week and average minutes of exercise per day, GV and serum growth hormone were analyzed.

Results: After 6 and 12 months of treatment, the GV, serum GHRH, GHBP, GH, IGF-1, and IGFBP-3 levels in the observation group were significantly higher than those in the control group, and HtSDS was significantly lower than that in the control group (P<0.01). After 12 months of treatment, the height of the observation group was significantly higher than that of the control group (P<0.05). There was no significant difference in the biochemical indicators between two groups (P>0.05). Average days of exercise per week and average minutes of exercise per day were positively correlated with GV and GHBP levels. Serum GHRH, GH, IGF-1, and IGFBP-3 levels were negatively correlated. Average minutes of exercise per day were negatively correlated with GV and GHBP levels. Serum GHRH, GH, IGF-1, and IGFBP-3 levels were positively correlated.

Conclusion: Regular and moderate stretching exercises combined with lysine-inositol VB12 can effectively promote height growth of children with ISS, which is clinically safe. The mechanism promotes serum GHRH, GHBP, GH, IGF-1, and IGFBP-3 levels.

Keywords: Curative effect; Exercise; Idiopathic short stature; Lysine-inositol VB12.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Body Height
  • Child
  • Dwarfism*
  • Growth Disorders / drug therapy
  • Growth Hormone / metabolism
  • Human Growth Hormone*
  • Humans
  • Insulin-Like Growth Factor Binding Protein 3
  • Insulin-Like Growth Factor I / metabolism
  • Lysine / pharmacology
  • Vitamin B 12 / pharmacology
  • Vitamin B 12 / therapeutic use

Substances

  • Insulin-Like Growth Factor I
  • Insulin-Like Growth Factor Binding Protein 3
  • Lysine
  • Human Growth Hormone
  • Vitamin B 12
  • Growth Hormone